



SEP 01 2004

1 Fw

PATENT
Attorney Docket No. 225602

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Desai et al.

Group Art Unit: 1653

Application No. 10/731,224

Examiner: Unassigned

Filed: December 9, 2003

For: COMPOSITIONS AND METHOD OF DELIVERY
OF PHARMACOLOGICAL AGENTS

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Applicants respectfully request that a corrected version of the Official Filing Receipt dated August 16, 2004 (copy enclosed with requested changes marked in red) be issued for the above-identified application.

Particularly, applicants respectfully request the following corrections:

Under Assignment For Published Patent Application, "America, BioSciences, Inc., Santa Monica, CA;" should be corrected to read -- American BioScience, Inc., Santa Monica, CA;--

Respectfully submitted,

By 
Bruce M. Gagala, Reg. No. 28,844
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600

Date: August 31, 2004

225602

Barth 2



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

American Bioscience

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLMS	IND CLMS
10/731,224	12/09/2003	1653	1386	225602		93	11

CONFIRMATION NO. 4904

23460

LEYDIG VOIT & MAYER, LTD
 TWO PRUDENTIAL PLAZA, SUITE 4900
 180 NORTH STETSON AVENUE
 CHICAGO, IL 60601-6780

FILING RECEIPT



OC000000013548507

Date Mailed: 08/16/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Neil P. Desai, Los Angeles, CA;
 Andrew Yang, Rosemead, CA;
 Sherry Xiaopei Ci, San Marino, CA;
 Tapas De, Los Angeles, CA;
 Vuong Trieu, Santa Monica, CA;
 Patrick Soon-Shiong, Los Angeles, CA;

LEYDIG, VOIT & MAYER
 RECEIVED

AUG 20 2004

PAT/TM Due Date Noted

Assignment For Published Patent Application

America, BioSciences, Inc., Santa Monica, CA;

→ American BioScience, Inc.,

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/432,317 12/09/2002
 and claims benefit of 60/526,544 12/03/2003
 and claims benefit of 60/526,773 12/04/2003
 and claims benefit of 60/527,177 12/05/2003

Foreign Applications

If Required, Foreign Filing License Granted: 08/15/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

JMG

LLP

Early Publication Request: No

**** SMALL ENTITY ****

Title

Compositions and methods of delivery of pharmacological agents

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).